MCID: HMR023
MIFTS: 45

Hemorrhagic Cystitis

Categories: Nephrological diseases

Aliases & Classifications for Hemorrhagic Cystitis

MalaCards integrated aliases for Hemorrhagic Cystitis:

Name: Hemorrhagic Cystitis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050859
UMLS 71 C0085692

Summaries for Hemorrhagic Cystitis

Disease Ontology : 12 A cystitis that is characterized by dysuria, hematuria and hemorrhage located in the lower urinary tract.

MalaCards based summary : Hemorrhagic Cystitis is related to cystitis and acute graft versus host disease. An important gene associated with Hemorrhagic Cystitis is IL11 (Interleukin 11), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Ciprofloxacin and Cytochrome P-450 Enzyme Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include lower urinary tract, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Hemorrhagic cystitis or haemorrhagic cystitis is an inflammation of the bladder defined by lower urinary... more...

Related Diseases for Hemorrhagic Cystitis

Diseases related to Hemorrhagic Cystitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 600)
# Related Disease Score Top Affiliating Genes
1 cystitis 31.6 TNF TLR4 JUN IL2
2 acute graft versus host disease 30.7 TNF IL2 CSF3
3 polyomavirus-associated nephropathy 30.4 LINC01194 EPRS1 CABIN1
4 graft-versus-host disease 30.0 TNF IL2 IL1B HLA-A
5 chronic graft versus host disease 29.9 CD4 ALB
6 acute leukemia 29.7 IL2 CSF3 CD8A CD34
7 capillary leak syndrome 29.5 IL2 CD8A ALB
8 cytomegalovirus infection 29.5 TNF IL1B HLA-A
9 allergic hypersensitivity disease 29.4 TNF PPIG IL2 CD4
10 severe combined immunodeficiency 29.4 JUN IL2 CSF3 CD4 CD34
11 sickle cell anemia 29.3 TNF HMOX1 CSF3 ALB
12 pulmonary edema 29.2 TNF IL1B HMOX1 CSF3
13 pancytopenia 29.2 CSF3 CD8A CD4 CD34 ALB
14 deficiency anemia 29.1 TNF IL11 HMOX1 CD34 ALB
15 leukemia, acute lymphoblastic 29.1 TOP1 PARP1 JUN IL2 CSF3 CD8A
16 progressive multifocal leukoencephalopathy 29.1 TNF LINC01194 IL2 CD8A CD4
17 urethritis 29.0 TNF TLR4 IL1B CD4
18 acute cystitis 29.0 TNF TLR4 IL1B EPRS1 CD4 ALB
19 keratitis, hereditary 28.9 TNF TLR4 IL1B CD4
20 suppression of tumorigenicity 12 28.9 TNF CD8A CD4 ALB
21 peritonitis 28.8 TNF TLR4 IL1B CSF3 ALB
22 human immunodeficiency virus infectious disease 28.8 TNF IL2 HLA-A CD8A CD4
23 immune deficiency disease 28.7 TNF JUN IL2 HLA-A CD4 CD34
24 typhoid fever 28.7 TNF TLR4 IL1B ALB
25 gastroenteritis 28.6 TNF IL1B CSF3 ALB
26 pneumocystosis 28.5 TNF CSF3 CD8A CD4 CABIN1 ALB
27 acute promyelocytic leukemia 28.4 TNF PARP1 JUN IL1B CSF3 CD34
28 common cold 28.4 TNF TLR4 IL1B CD4 ALB
29 bacterial infectious disease 28.3 TNF TLR4 IL1B CSF3 CD8A CD4
30 pulmonary tuberculosis 28.2 TNF TLR4 IL2 IL1B ALB
31 stomatitis 28.2 TNF TLR4 IL2 IL1B CSF3 CD4
32 pyelonephritis 28.2 TNF TLR4 IL1B HLA-A CSF3 ALB
33 respiratory failure 28.1 TNF TLR4 JUN IL1B CD4 ALB
34 bronchopneumonia 27.9 TNF TLR4 IL1B CD8A CD4 ALB
35 neutropenia 27.9 TOP1 TNF TLR4 IL2 IL1B IL11
36 aplastic anemia 27.7 TNF IL2 IL1B IL11 HLA-A CSF3
37 lymphoma, non-hodgkin, familial 27.7 TOP1 TNF LINC01194 IL2 HLA-A CSF3
38 hematologic cancer 27.6 TOP1 TNF IL2 IL11 HLA-A CSF3
39 testicular disease 27.4 TNF TLR4 IL2 IL1B CD8A CD4
40 thrombocytopenia 27.3 TOP1 TNF TLR4 IL2 IL1B IL11
41 neuroblastoma 27.3 TOP1 TNF PARP1 JUN IL2 IL1B
42 systemic lupus erythematosus 26.9 TNF TLR4 IL2 IL1B HMOX1 HLA-A
43 cervical cancer 26.8 TNF TLR4 PARP1 JUN IL2 IL1B
44 myelodysplastic syndrome 26.7 TOP1 TNF IL2 IL1B IL11 HLA-A
45 myeloma, multiple 26.7 TNF TLR4 JUN IL2 IL1B IL11
46 leukemia, acute myeloid 26.4 TOP1 TNF PARP1 JUN IL2 IL1B
47 third ventricle chordoid glioma 10.4 CD4 CD34
48 radiation cystitis 10.4
49 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.3
50 hydronephrosis 10.3

Graphical network of the top 20 diseases related to Hemorrhagic Cystitis:



Diseases related to Hemorrhagic Cystitis

Symptoms & Phenotypes for Hemorrhagic Cystitis

MGI Mouse Phenotypes related to Hemorrhagic Cystitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CABIN1 CD34 CD4 CD8A CSF3 HLA-A
2 immune system MP:0005387 10.03 ALB CABIN1 CD34 CD4 CD8A CSF3
3 integument MP:0010771 9.65 CD34 CD4 CD8A CSF3 EPRS1 IL1B
4 mortality/aging MP:0010768 9.47 ALB CABIN1 CD4 CD8A EPRS1 HLA-A

Drugs & Therapeutics for Hemorrhagic Cystitis

Drugs for Hemorrhagic Cystitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2 Cytochrome P-450 Enzyme Inhibitors Phase 4
3 Fluoroquinolones Phase 4
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
6
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
8
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
9 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
10
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
11
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
12
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
13
Etoposide Approved Phase 3 33419-42-0 36462
14
Busulfan Approved, Investigational Phase 3 55-98-1 2478
15
leucovorin Approved Phase 3 58-05-9 6006 143
16
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
19 Thymoglobulin Phase 3
20 Protective Agents Phase 3
21 glucocorticoids Phase 3
22 Gastrointestinal Agents Phase 3
23 Methylprednisolone Acetate Phase 3
24 Hormones Phase 3
25 Antineoplastic Agents, Hormonal Phase 3
26 Antiemetics Phase 3
27 Hormone Antagonists Phase 3
28 Neuroprotective Agents Phase 3
29 Anti-Inflammatory Agents Phase 3
30 Antilymphocyte Serum Phase 3
31 polysaccharide-K Phase 3
32 Immunoglobulins, Intravenous Phase 3
33 Rho(D) Immune Globulin Phase 3
34 gamma-Globulins Phase 3
35 Immunoglobulin A Phase 3
36 Immunoglobulin G Phase 3
37 Immunoglobulin M Phase 3
38 Anti-Infective Agents Phase 3
39 Cyclosporins Phase 3
40 Antifungal Agents Phase 3
41 Dermatologic Agents Phase 3
42 Calcineurin Inhibitors Phase 3
43 Etoposide phosphate Phase 3
44 Antimetabolites Phase 3
45 Vitamin B Complex Phase 3
46 Folate Phase 3
47 Folic Acid Antagonists Phase 3
48
Bilirubin Phase 3 69853-43-6, 635-65-4 21252250 5280352
49 Vitamin B9 Phase 3
50
Misoprostol Approved Phase 2 59122-46-2 5282381

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients Completed NCT01789203 Phase 4 Ciprofloxacin;placebo
2 Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
3 Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb) Active, not recruiting NCT01445821 Phase 3 Cyclophosphamide;Mesna;rATG;Methylprednisolone;Filgrastim;Fludarabine
4 Maximizing Outcome of Multiple Sclerosis Transplantation: "MOST" Trial Active, not recruiting NCT03342638 Phase 3 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
5 Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT) Not yet recruiting NCT04390113 Phase 3
6 Randomized Trial of Busulfan or Total Body Irradiation Conditioning Regimens for Children With Acute Lymphoblastic Leukemia Terminated NCT00002961 Phase 3 cyclophosphamide;cyclosporine;etoposide;methotrexate;Busulfan;Mesna
7 A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis Unknown status NCT02174536 Phase 2
8 Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial Unknown status NCT02895724 Phase 2 Medical Oxygen
9 A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis Completed NCT02172963 Phase 1, Phase 2
10 An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven®) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy Completed NCT01561352 Phase 2 activated recombinant human factor VII
11 The Effects of 12 mg/kg Intravenous Mesna on Plasma Total Homocysteine Concentration in Patients With End-stage Renal Disease Requiring Hemodialysis Completed NCT00524199 Phase 2 Mesna
12 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study Completed NCT00976300 Phase 2 Cyclosporine A;Cyclophosphamide
13 A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies Completed NCT01336712 Phase 2
14 Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders Completed NCT00028730 Phase 2 cyclophosphamide;fludarabine phosphate;thiotepa
15 Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor Completed NCT00730314 Phase 1, Phase 2
16 Third Party Anti-viral Cytotoxic T-cells (CTLs) for Treatment of Viral Infections in Immunocompromised Patients Recruiting NCT02532452 Phase 2
17 Clinical Phase II Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy Recruiting NCT02814864 Phase 2 Mesenchymal Stromal Cell (MSC) injections
18 Donor-Derived Anti-viral CTLs for Treatment of Viral Infections After Allogeneic Stem Cell Transplant Recruiting NCT02048332 Phase 1, Phase 2
19 A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation (ITN073ST) Recruiting NCT03577431 Phase 1, Phase 2 cyclophosphamide;mesna;everolimus
20 Adoptive Cord Blood ImmunotHerapy Using Expanded Cord Blood T Cells for EBV, CMV, BKV and Adenovirus Reactivation/Infection or ProphylaxiS Recruiting NCT03594981 Phase 1, Phase 2
21 A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant Active, not recruiting NCT01295645 Phase 2 Cidofovir
22 Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
23 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
24 Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas Active, not recruiting NCT01458366 Phase 1, Phase 2 Bendamustine;Ofatumumab;Carboplatin;Etoposide
25 A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies Active, not recruiting NCT02793544 Phase 2 Fludarabine;Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;Busulfan;Cyclophosphamide 50mg/kg/day IV on Days -2,-1;Cyclophosphamide 50mg/kg/day IV on Days -5,-4;Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;Sirolimus;Mycophenolate mofetil;G-CSF;Pre-HCT Mesna on Days -6 and -5;Pre-HCT Mesna on Days -2 and -1;Pre-HCT Mesna on Days -5 and -4;Post-HCT Mesna
26 A Multicenter, Double-blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-10 With Placebo in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis Not yet recruiting NCT03129126 Phase 2 Placebo;LP-10
27 Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies Terminated NCT00539656 Phase 1, Phase 2
28 Protocol for Related Donor Hematopoietic Stem Cell Transplantation (HSCT) for Treatment of Symptomatic Genetic Lymphohematological Diseases Terminated NCT02512679 Phase 2 Cyclophosphamide Dose Level 1;Cyclophosphamide Dose Level 2;Cyclophosphamide Dose Level 3;Cyclophosphamide Dose Level 4
29 Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial Terminated NCT00282438 Phase 1, Phase 2
30 A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation Withdrawn NCT03654040 Phase 1, Phase 2 cyclophosphamide;mesna;everolimus
31 Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study Completed NCT01816646 Phase 1 Cidofovir;Probenecid
32 A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Completed NCT00455052 Phase 1 XMT-1001
33 UARK 2003-18, A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma Completed NCT00089453 Phase 1 Dexamethasone;Cyclophosphamide;Melphalan;Fludarabine;Bortezomide;Interleukin
34 Administration of Virus-Specific Cytotoxic T-Lymphocytes for the Prophylaxis and Therapy of Adenovirus Infection Post Allogeneic Stem Cell Transplant Completed NCT00590083 Phase 1
35 Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma Completed NCT00742924 Phase 1 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;zoledronic acid;Mesna
36 A Phase I Study of Bone Marrow Stromal Cell Infusions to Treat Acute Graft Versus Host Disease, Marrow Failure and Tissue Injury After Allogeneic Stem Cell Transplantation Completed NCT01633229 Phase 1
37 Novel Antigens Targeted by ex Vivo Expanded T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation Recruiting NCT03180216 Phase 1
38 Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus Infections Post Allogeneic Stem Cell Transplant Recruiting NCT02510417 Phase 1
39 Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients Active, not recruiting NCT01655836 Phase 1
40 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
41 Prospective Study Based on Genetic Polymorphisms Related to Individual Variations of Side Effects of Cyclophosphamide in Systemic Lupus Erythematosus Treatment Completed NCT01689350
42 A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix Completed NCT00193804
43 Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis. Active, not recruiting NCT03103776
44 High-dose Cyclophosphamide for the Treatment of ROHHAD (Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation) Syndrome Active, not recruiting NCT02441491 Cyclophosphamide
45 Post-transplant Cyclophosphamide for HLA-haploidentical Transplantation in Wiskott-Aldrich Syndrome Enrolling by invitation NCT03198195
46 Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study Withdrawn NCT00956176 Cidofovir

Search NIH Clinical Center for Hemorrhagic Cystitis

Genetic Tests for Hemorrhagic Cystitis

Anatomical Context for Hemorrhagic Cystitis

The Foundational Model of Anatomy Ontology organs/tissues related to Hemorrhagic Cystitis:

19
Lower Urinary Tract

MalaCards organs/tissues related to Hemorrhagic Cystitis:

40
Bone, Bone Marrow, T Cells, Kidney, Prostate, Breast, Lung

Publications for Hemorrhagic Cystitis

Articles related to Hemorrhagic Cystitis:

(show top 50) (show all 1408)
# Title Authors PMID Year
1
Re: Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis. 54 61
18199361 2007
2
Re: Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis. 61 54
18199362 2007
3
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis. 61 54
17980069 2007
4
Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients. 61
32153257 2020
5
Successful Treatment of Urinary Bladder Hemangiosarcoma by Partial Cystectomy in a Dog. 61
32412336 2020
6
Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. 61
32004700 2020
7
[Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of 12 Patients with Acute Leukemia in Tropical Area]. 61
32552930 2020
8
A case series of post-transplant cyclophosphamide in unrelated donor hematopoietic transplantation for aplastic anemia. 61
32504863 2020
9
Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation. 61
31876431 2020
10
BK virus infection in allogeneic hematopoietic cell transplantation: An update on pathogenesis, immune responses, diagnosis and treatments. 61
32526327 2020
11
Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease. 61
32519048 2020
12
Alum irrigation for the treatment of adenovirus induced hemorrhagic cystitis in a kidney transplant recipient. 61
32055446 2020
13
Re: Superselective Vesical Artery Embolization in the Management of Intractable Hematuria Secondary to Hemorrhagic Cystitis. 61
32401584 2020
14
Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. 61
32417488 2020
15
Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review. 61
32356687 2020
16
α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. 61
32415495 2020
17
BK virus encephalitis and end-stage renal disease in a child with hematopoietic stem cell transplantation. 61
32412694 2020
18
Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease. 61
32314173 2020
19
Analysis of viruses present in urine from patients with interstitial cystitis. 61
32447589 2020
20
Outcome of a 980-nm diode laser coagulation in women with radiation-induced hemorrhagic cystitis: a single-center retrospective study. 61
32304002 2020
21
Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation. 61
32025839 2020
22
[Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation]. 61
32311895 2020
23
Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders. 61
31751770 2020
24
Effects and long-term follow-up of using umbilical cord blood-derived mesenchymal stromal cells in pediatric patients with severe BK virus-associated late-onset hemorrhagic cystitis after unrelated cord blood transplantation. 61
31944495 2020
25
Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children. 61
32224144 2020
26
BK polyomavirus diversity-Why viral variation matters. 61
32128960 2020
27
Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. 61
32074279 2020
28
Ado-Trastuzumab Emtansine-Induced Hemorrhagic Cystitis in a Patient With Breast Cancer. 61
32053521 2020
29
QUANTIFICATION OF 3-HYDROXYPROPYL MERCAPTURIC ACID IN THE URINE OF PATIENTS WITH BREAST CANCER TO MONITOR CYCLOPHOSPHAMIDE TOXICITY. 61
32079909 2020
30
Hyperbaric Oxygen Therapy of an Adolescent Stem Cell Transplantation Recipient with Hemorrhagic Cystitis and BK Virus. 61
32455043 2020
31
Hyperbaric oxygen for refractory hemorrhagic cystitis after stem cell transplantation: case report. 61
32176953 2020
32
Pathogenicity of BK virus on the urinary system. 61
32395331 2020
33
Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children. 61
31527820 2020
34
Serious Hemorrhagic Complications After Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy With Defibrotide in Pediatric Patient With Myelodysplastic Syndrome. 61
32432059 2020
35
Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. 61
30963398 2020
36
Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications. 61
31930750 2020
37
Comparison of Rapid Hydration and Standard Hydration Prior to Ifosfamide Administration in Pediatric Patients: A Safety and Efficacy Study. 61
32265609 2020
38
BK polyomavirus-pathogen, paradigm and puzzle. 61
31891401 2019
39
Prospective Analysis of Hemorrhagic Cystitis and BK Viremia in Allogeneic Hematopoietic Stem Cell Transplantation 61
31852035 2019
40
Neutropenia and renal dysfunction due to intravesical cidofovir for virus-associated hemorrhagic cystitis after kidney and allogenic hematopoietic stem cell transplantations. 61
31571390 2019
41
The natural history of BK polyomavirus and the host immune response after stem cell transplantation. 61
31851312 2019
42
Epidemiology and Outcomes of Early-Onset and Late-Onset Adenovirus Infections in Kidney Transplant Recipients. 61
32128332 2019
43
Successful Outcome in Patients with Fanconi Anemia Undergoing T Cell-Replete Mismatched Related Donor Hematopoietic Cell Transplantation Using Reduced-Dose Cyclophosphamide Post-Transplantation. 61
31306778 2019
44
Canadian Urological Association Best Practice Report: Pediatric hemorrhagic cystitis. 61
31763977 2019
45
Uroprotective effect of pantoprazole against cyclophosphamide-induced cystitis in mice. 61
30874926 2019
46
Severe hemorrhagic cystitis caused by the BK polyomavirus is associated with decreased survival post-allogeneic hematopoietic stem cell transplantation. 61
31054192 2019
47
Results of Allogenic Hematopoietic Stem Cell Transplantation in Fanconi Anemia Caused by Bone Marrow Failure: Single-Regimen, Single-Center Experience of 14 Years. 61
31199982 2019
48
[Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen]. 61
31775481 2019
49
Superselective vesical artery embolization in the management of intractable hematuria secondary to hemorrhagic cystitis. 61
30560299 2019
50
Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME. 61
31401154 2019

Variations for Hemorrhagic Cystitis

Expression for Hemorrhagic Cystitis

Search GEO for disease gene expression data for Hemorrhagic Cystitis.

Pathways for Hemorrhagic Cystitis

Pathways related to Hemorrhagic Cystitis according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF TLR4 JUN IL2 IL1B IL11
2
Show member pathways
13.35 TNF IL2 IL1B IL11 HMOX1 HLA-A
3
Show member pathways
13.31 TNF JUN IL2 IL1B IL11 CSF3
4
Show member pathways
12.94 TNF TLR4 JUN IL1B HLA-A CD4
5
Show member pathways
12.85 TNF IL2 IL1B HLA-A CD8A CD4
6
Show member pathways
12.81 TNF TLR4 JUN IL2 IL1B HLA-A
7
Show member pathways
12.73 TNF TLR4 JUN IL1B HMOX1
8
Show member pathways
12.6 TNF TLR4 JUN IL2 IL1B CD4
9
Show member pathways
12.56 TNF TLR4 JUN IL2 IL1B CD8A
10 12.52 TNF IL2 IL1B HMOX1 CD8A CD34
11 12.4 TNF TLR4 JUN IL1B
12
Show member pathways
12.39 JUN IL2 CD4 CABIN1
13
Show member pathways
12.34 TNF JUN IL1B CSF3
14
Show member pathways
12.34 TNF IL2 IL1B ALB
15 12.34 TNF JUN IL2 HLA-A CD4
16 12.32 TNF TLR4 JUN IL1B
17 12.28 TNF TLR4 JUN IL1B
18
Show member pathways
12.27 TNF TLR4 JUN IL1B
19 12.25 TNF TLR4 JUN IL1B
20
Show member pathways
12.22 TNF JUN IL2 IL1B
21
Show member pathways
12.21 TNF TLR4 PARP1 IL1B
22
Show member pathways
12.21 TOP1 TNF PARP1 JUN
23
Show member pathways
12.17 TNF TLR4 JUN IL1B IL11
24 12.13 HLA-A CD8A CD4 CD34
25 12.1 TNF JUN IL1B HMOX1
26
Show member pathways
12.03 JUN IL2 CABIN1
27
Show member pathways
12.03 TLR4 JUN IL2 IL1B
28 12.01 TNF TLR4 IL2 IL1B
29 12 TNF TLR4 JUN IL2 IL1B
30 11.93 TNF TLR4 PARP1 IL1B
31
Show member pathways
11.93 JUN IL2 IL1B HLA-A CD8A CD4
32
Show member pathways
11.87 TNF TLR4 JUN IL2 IL1B CD4
33 11.86 TNF TLR4 JUN IL1B IL11
34 11.78 TNF TLR4 JUN IL1B
35
Show member pathways
11.77 TNF JUN IL2 CABIN1
36 11.76 TNF IL2 IL11 CSF3 CD8A CD4
37 11.7 TNF IL2 IL1B CD8A CD4 CD34
38
Show member pathways
11.68 TNF JUN IL2 IL1B
39 11.67 TNF IL1B HMOX1 CSF3
40 11.62 TNF TLR4 IL1B
41
Show member pathways
11.62 TNF JUN IL2 HLA-A CD8A
42 11.6 TNF IL2 IL1B CD8A CD4 CD34
43 11.57 TNF JUN IL2
44 11.55 TNF TLR4 IL1B CSF3
45 11.54 TNF IL1B CSF3
46 11.53 TNF TLR4 IL1B
47 11.52 TNF JUN IL2 IL1B
48 11.5 TNF JUN IL1B
49 11.5 TNF IL1B IL11 CSF3 CD8A CD4
50 11.36 TNF TLR4 IL1B HMOX1

GO Terms for Hemorrhagic Cystitis

Cellular components related to Hemorrhagic Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 TNF TLR4 CD8A CD4 CD34

Biological processes related to Hemorrhagic Cystitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 TNF TLR4 PARP1 JUN IL2 IL1B
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 TNF TLR4 JUN CD4
3 positive regulation of protein phosphorylation GO:0001934 9.87 TNF IL2 IL1B CD4
4 cellular response to lipopolysaccharide GO:0071222 9.85 TNF TLR4 IL1B CSF3
5 positive regulation of JNK cascade GO:0046330 9.79 TNF TLR4 IL1B
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.77 TNF TLR4 IL1B
7 positive regulation of T cell proliferation GO:0042102 9.76 IL2 IL1B CD4
8 immune response GO:0006955 9.76 TNF TLR4 IL2 IL1B HLA-A CSF3
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 TNF JUN HMOX1
10 positive regulation of interleukin-6 production GO:0032755 9.73 TNF TLR4 IL1B
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.72 TNF TLR4 IL1B HMOX1 CD4
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 TNF TLR4 IL1B
13 positive regulation of interleukin-6 secretion GO:2000778 9.69 TNF TLR4 IL1B
14 positive regulation of inflammatory response GO:0050729 9.67 TNF TLR4 IL2 IL1B
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 TNF TLR4 IL1B
16 positive regulation of monocyte differentiation GO:0045657 9.61 JUN CD4
17 positive regulation of interleukin-8 production GO:0032757 9.61 TNF TLR4 IL1B
18 regulation of establishment of endothelial barrier GO:1903140 9.6 TNF IL1B
19 positive regulation of fever generation GO:0031622 9.54 TNF IL1B
20 cytokine-mediated signaling pathway GO:0019221 9.5 TNF IL2 IL1B IL11 HMOX1 CSF3
21 sequestering of triglyceride GO:0030730 9.49 TNF IL1B
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IL1B
23 positive regulation of chemokine biosynthetic process GO:0045080 9.43 TNF IL1B HMOX1
24 positive regulation of interferon-gamma production GO:0032729 9.02 TNF TLR4 IL2 IL1B HLA-A

Molecular functions related to Hemorrhagic Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TNF TLR4 PARP1 JUN HMOX1 EPRS1
2 enzyme binding GO:0019899 9.55 PARP1 JUN HMOX1 CSF3 CD4
3 cytokine activity GO:0005125 9.02 TNF IL2 IL1B IL11 CSF3

Sources for Hemorrhagic Cystitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....